CAR-T cell therapy in hematology malignancies: breaking barriers, engineering the future
- 1Laboratorio de Inmunología y Virología, Departamento de Microbiología e Inmunología, Universidad Autónoma de Nuevo León, Facultad de Ciencias Biológicas, San Nicolás de los Garza
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative approach for the treatment of hematological malignancies by enabling the genetic modification of a patient’s own T cells to recognize and eliminate malignant cells in an MHC-independent manner. In this mini review, we provide an overview of the fundamental principles of CAR-T cell therapy and discuss selected combinatorial strategies investigated for the development of next-generation CAR-T products in hematologic malignancies. We also discuss approaches combining CAR-T cells with other therapeutic modalities and consider challenges of this technology and mention potential future directions in the field. The aim is to briefly illustrate how advances in cellular engineering and biological understanding are contributing to the development of CAR-T cell therapies, while providing clinicians and researchers with a concise overview of their application in hematologic malignancies.
Related
- Precision cooling assists electrical stimulation: Breaking selectivity barriers in nerve control
- Stealthy lentiviral vectors: Breaking the barriers to systemic in vivo gene delivery
- Intelligent immunotherapy: AI-driven optimization of CAR-T therapy in hematologic malignancies
- Circulating tumor DNA for prognosis in hematologic malignancies receiving immune checkpoint inhibitors or chimeric antigen receptor T-cell therapy: a systematic review and meta-analysis
- Engineering the Pseudomonas aeruginosa virus-isolation host viPAO1 reveals how host genetic barriers shape recoverable phage diversity
BibTeX
@article{alvizobaez2026cart,
title = {{CAR-T cell therapy in hematology malignancies: breaking barriers, engineering the future}},
author = {Cynthia Aracely Alvizo-Báez and Ana Karina Chavez-Escamilla and Santiago Saavedra-Alonso and Luis Daniel Terrazas-Armendáriz and Cristina Rodríguez-Padilla and Juan Manuel Alcocer-González and Ashanti Concepción Uscanga-Palomeque},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1974018},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1974018/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - CAR-T cell therapy in hematology malignancies: breaking barriers, engineering the future
AU - Cynthia Aracely Alvizo-Báez
AU - Ana Karina Chavez-Escamilla
AU - Santiago Saavedra-Alonso
AU - Luis Daniel Terrazas-Armendáriz
AU - Cristina Rodríguez-Padilla
AU - Juan Manuel Alcocer-González
AU - Ashanti Concepción Uscanga-Palomeque
PY - 2026
DA - 2026/11/03
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1974018
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1974018/full
AB - Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative approach for the treatment of hematological malignancies by enabling the genetic modification of a patient’s own T cells to recognize and eliminate malignant cells in an MHC-independent manner. In this mini review, we provide an overview of the fundamental principles of CAR-T cell therapy and discuss selected combinatorial strategies investigated for the development of next-generation CAR-T products in hematologic malignancies. We also discuss approaches combining CAR-T cells with other therapeutic modalities and consider challenges of this technology and mention potential future directions in the field. The aim is to briefly illustrate how advances in cellular engineering and biological understanding are contributing to the development of CAR-T cell therapies, while providing clinicians and researchers with a concise overview of their application in hematologic malignancies.
SN - 1664-3224
ER -